Shaziya Jabeen¹ *, Neelam Khan¹ , Avika Joshi ¹ , Sana Khan² and Pragya Gawande³

¹ Amaltas Institute of Pharmacy, Amaltas University, Dewas, M.P, India
² Samrat Vikramaditya Vishwavidhyalay, Ujain, M.P, India
³ Guru Ghasidas Vishwavidyalaya, Bilaspur, Chattisgarh, India

*Corresponding Author: Shaziya Jabeen, Amaltas Institute of Pharmacy, Amaltas University, Dewas, M.P, India.

Received: February 03, 2026 Published: February 28, 2026

Abstract

In present context, development of novel Antimicrobials is become an urgent need to addressing AMR. In the present study, some novel substituted Bezimidazole derivatives have been designed and subjected to molecular- docking against E. coli and S. aureus by using Auto Dock Vina software. Among all 10 designed derivatives BI-B show highest binding affinity and molecular interaction against selected target. ADMET prediction by using Molsoft L.L.C. Software that help to predicts both physicochemical significant descriptors and pharmacokinetic significant properties. Then 4-chloro-phenyl benzimidazole and 4-nitro-phenyl benzimidazole derivatives were synthesized and structurally characterized by 1H NMR spectroscopy that confirm the structure of synthesized derivatives. In vitro antimicrobial analysis of all the synthesized compounds were performed by agar plate technique. The results indicate that the synthesized compounds show considerable antimicrobial action against the selected microorganism at 31.25 µm concentrations as compared to ampicillin as standard.

Keywords: Antimicrobial; Benzimidazole; Molecular Docking; ADMET; (E. coli); (S. aureus)

References

1. Al-Obaidi MMY., et al. “Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis”. Antimicrobial Resistance and Infection Control 14 (2025): 10.
2. World Health Organization. Global antibiotic resistance surveillance report 2025. Geneva: World Health Organization. (Report on antibiotic resistance trends and priority pathogens) (2025).
3. World Health Organization. WHO releases new reports on new tests and treatments in development for bacterial infections. Geneva: World Health Organization (2025).
4. O’Neill J., et al. “Global action urgently needed to tackle antimicrobial resistance”. npj Antimicrobe Agents Research (Review outlining AMR challenges & R&D barriers) (2025).
5. Salahuddin A., et al. “Benzimidazoles: a biologically active compounds”. Arabian Journal of Chemistry1 (2017): S157-S173.
6. Keri RS., et al. “Comprehensive review in current developments of benzimidazole-based medicinal chemistry”. Chemical Biology and Drug Design 1 (2015): 19-65.
7. Zhang HZ., et al. “Recent advance in oxazole, thiazole and benzimidazole derivatives as antimicrobial agents”. European Journal of Medicinal Chemistry 144 (2018): 444-492.
8. Narasimhan B., et al. “Benzimidazole: a medicinally important heterocyclic scaffold”. Medicinal Chemistry Research 28 (2019): 1-42.
9. Al-Mutairi MS., et al. “Design, synthesis and antimicrobial evaluation of novel benzimidazole derivatives”. Journal of Molecular Structure 1230 (2021): 129833.
10. Clinical and Laboratory Standards Institute (CLSI). “Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard.” 11^th Wayne (PA): CLSI. CLSI document M07 (2018).

Citation

Citation: Shaziya Jabeen., et al. “In-Vitro and In-Vivo Analysis of Novel Substituted Benzimidazole Derivatives as Antimicrobial Agents". Acta Scientific Pharmaceutical Sciences 10.3 (2026): 14-22.

Copyright

Copyright: © 2026 Shaziya Jabeen., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.